Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

SVNTQ 0.0019
price chart
Bridgewater-based Savient Pharmaceuticals OKd for Chapter 11 plan
Savient Pharmaceuticals Inc., a developer of a treatment for gout before its business was sold, got approval of a liquidating Chapter 11 plan, with U.S.
Savient Pharmaceuticals Files for Bankruptcy
Oct. 14 (Bloomberg) -- Savient Pharmaceuticals Inc., the developer of a treatment for gout, sought bankruptcy protection and court approval to sell its assets to a US WorldMeds LLC unit for $55 million, the company said.
Savient Pharmaceuticals files for Chapter 11 bankruptcy  Reuters
Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks To ...  PR Newswire (press release)
Related articles »  
Savient Pharmaceuticals gets approval from US Bankruptcy Court to sell all ...
Savient Pharmaceuticals filed for bankruptcy in October. Citing a filing in the Bankruptcy Court in Wilmington, Delaware, Bloomberg reported that Savient had debts amounting to $260 million and only had assets of $74 million. The largest shareholder of ...
Bankrupt Savient Gets OK For $120M Sale To Crealta  Law360 (subscription)
Related articles »  
GTCR's Crealta To Buy Savient Pharmaceuticals
By Ben Fox Rubin. Biopharmaceutical firm Savient Pharmaceuticals Inc. agreed to sell itself to Crealta Pharmaceuticals LLC for $120.4 million, following a bankruptcy-court approved auction.
Savient acquired by Crealta Pharmaceuticals in $120M bankruptcy auction  NJBIZ
Crealta to acquire all assets of Savient Pharmaceuticals  News-Medical.net
Related articles »  
Savient Pharma Unveils Ch. 11 Plan
Law360, New York (February 10, 2014, 7:01 PM ET) -- Drug developer Savient Pharmaceuticals Inc. unveiled its Chapter 11 plans in Delaware bankruptcy court Monday, calling for the liquidation of its U.S.
Related articles »  
Savient Pharmaceuticals, Inc. (SVNT): Are Hedge Funds Right About This Stock?
When looking at the hedgies we track, William Leland Edwards's Palo Alto Investors had the most valuable position in Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), worth close to $11.8 million, accounting for 1.4% of its total 13F portfolio. Coming in ...
Related articles »  
DEADLINE ALERT: Rigrodsky & Long, PA Reminds Shareholders Of Savient ...
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of Savient Pharmaceuticals, Inc. (“Savient” or the “Company”) (OTC QB: SVNTQ) of an upcoming deadline involving a securities ...
Related articles »  
Trying to Get a Handle on Savient Pharmaceuticals' Valuation
It is the same company that was selling for $22/share a few days ago. There have been no accounting irregularities. No new problems with the drug have been discovered.
Savient Pharma: Still Struggling To Grow KRYSTEXXA Sales
After reporting Q3 earnings, Savient Pharma (SVNT) plummeted back to a $1 from the meteoric rise to nearly $3 during the quarter.
Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity
Savient is an emerging biotechnology company that is in the early stages of launching its first product, Krystexxa (pegloticase) for chronic refractory gout patients.